We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $8.97 in the latest trading session, marking a -1.21% move from the prior day. This change lagged the S&P 500's daily loss of 0.79%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 1.55%.
The infectious disease drug developer's shares have seen an increase of 10.6% over the last month, surpassing the Medical sector's gain of 5.5% and the S&P 500's gain of 4.28%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release. The company's earnings per share (EPS) are projected to be $0.16, reflecting a 6.67% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $125.77 million, up 3.11% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.82 per share and revenue of $535 million, indicating changes of +36.67% and +4.87%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 11.07. For comparison, its industry has an average Forward P/E of 20.52, which means Adma Biologics is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 108, positioning it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Suffers a Larger Drop Than the General Market: Key Insights
Adma Biologics (ADMA - Free Report) closed at $8.97 in the latest trading session, marking a -1.21% move from the prior day. This change lagged the S&P 500's daily loss of 0.79%. Meanwhile, the Dow lost 0.26%, and the Nasdaq, a tech-heavy index, lost 1.55%.
The infectious disease drug developer's shares have seen an increase of 10.6% over the last month, surpassing the Medical sector's gain of 5.5% and the S&P 500's gain of 4.28%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release. The company's earnings per share (EPS) are projected to be $0.16, reflecting a 6.67% increase from the same quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $125.77 million, up 3.11% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $0.82 per share and revenue of $535 million, indicating changes of +36.67% and +4.87%, respectively, compared to the previous year.
Investors might also notice recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #3 (Hold).
Looking at its valuation, Adma Biologics is holding a Forward P/E ratio of 11.07. For comparison, its industry has an average Forward P/E of 20.52, which means Adma Biologics is trading at a discount to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 108, positioning it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.